Expression profiling of murine intestinal adenomas reveals early deregulation of multiple matrix metalloproteinase (Mmp) genes

Journal of Pathology

Volumn 206, Issue 1, 2005, Pages 100-110

  Martinez, Cristina ^a,b   Bhattacharya, Sumit ^c   Freeman, Tom ^c   Churchman, Michael ^d   Ilyas, Mohammad ^a,e  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c MRC Rosalind Franklin Centre for Genomics Research   (United Kingdom)

^d IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^e LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

Expression profiling; Intestine; Mmp; Mouse; Tumourigenesis

Indexed keywords

ANTINEOPLASTIC AGENT; COLLAGENASE 3; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE INHIBITOR; STROMELYSIN 2; WNT PROTEIN;

ADENOMA; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CELL ADHESION; CONTROLLED STUDY; GENE; GENE EXPRESSION; INTESTINE EPITHELIUM; INTESTINE MUCOSA; INTESTINE TUMOR; MATRIX METALLOPROTEINASE GENE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STROMA; UNINDEXED SEQUENCE;

ADENOMA; ANIMALS; COLLAGENASES; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; INTESTINAL MUCOSA; INTESTINAL NEOPLASMS; MATRIX METALLOPROTEINASE 10; MATRIX METALLOPROTEINASE 13; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASES; MATRIX METALLOPROTEINASES, MEMBRANE-ASSOCIATED; METALLOENDOPEPTIDASES; MICE; MICE, MUTANT STRAINS; NEOPLASM STAGING; NEOPLASMS, MULTIPLE PRIMARY; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 18144417862     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.1755     Document Type: Article

References (40)

1. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-767.
2. Ilyas M, Straub J, Tomlinson IPM, Bodmer WF. Genetic pathways in colorectal and other cancers. Eur J Cancer 1999; 35: 335-351.
3. Ilyas M, Tomlinson IPM, Rowan A, Pignatelli M, Bodmer WF. Beta-catenin mutations in cell lines established from human colorectal cancers. Proc Natl Acad Sci U S A 1997; 94: 10330-10334.
4. Rowan AJ, Lamlum H, Ilyas M, Wheeler J, Straub J, Papadopoulou A, et al. APC mutations in sporadic colorectal tumors: A mutational 'hotspot' and interdependence of the 'two hits'. Proc Natl Acad Sci U S A 2000; 97: 3352-3357.
5. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997; 275: 1787-1790.
6. Roose J, Clevers H. TCF transcription factors: molecular switches in carcinogenesis. Biochim Biophys Acta - Rev Cancer 1999; 1424: M23-M37.
7. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, et al. Identification of c-MYC as a target of the APC pathway. Science 1998; 281: 1509-1512.
8. Tetsu O, McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999; 398: 422-426.
9. Lamlum H, Papadopoulou A, Ilyas M, Rowan A, Gillet C, Hanby A, et al. APC mutations are sufficient for the growth of early colorectal adenomas. Proc Natl Acad Sci U S A 2000; 97: 2225-2228.
10. Harada N, Tamai Y, Ishikawa T, Sauer B, Takaku K, Oshima M, et al. Intestinal polyposis in mice with a dominant stable mutation of the beta-catenin gene. EMBO J 1999; 18: 5931-5942.
11. Su LK, Kinzler KW, Vogelstein B, Preisinger AC, Moser AR, Luongo C, et al. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the Apc gene. Science 1992; 256: 668-670.
12. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nature Rev Cancer 2002; 2: 161-174.
13. Wilding J, Straub J, Bee J, Churchman M, Bodmer W, Dickson C, et al. Cyclin D1 is not an essential target of beta-catenin signaling during intestinal tumorigenesis, but it may act as a modifier of disease severity in multiple intestinal neoplasia (Min) mice. Cancer Res 2002; 62: 4562-4565.
14. Benjamini Y, Hochberg Y. Controlling the false discovery rate - a practical and powerful approach to multiple testing. J R Stat Soc Ser B - Method 1995; 57: 289-300.
15. Schilham MW, Clevers H. HMG box containing transcription factors in lymphocyte differentiation. Semin Immunol 1998; 10: 127-132.
16. Kanai-Azuma M, Kanai Y, Gad JM, Tajima Y, Taya C, Kurohmaru M, et al. Depletion of definitive gut endoderm in Sox17-null mutant mice. Development 2002; 129: 2367-2379.
17. Chen XD, Halberg RB, Ehrhardt WM, Torrealba J, Dove WF. Clusterin as a biomarker in murine and human intestinal neoplasia. Proc Natl Acad Sci U S A 2003; 100: 9530-9535.
18. van de Wetering M, Sancho E, Verweij C, de Lau W, Oving I, Hurlstone A, et al. The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 2002; 111: 241-250.
19. Notterman DA, Alon U, Sierk AJ, Levine AJ. Transcriptional gene expression profiles of colorectal adenoma, adenocarcinoma, and normal tissue examined by oligonucleotide arrays. Cancer Res 2001; 61: 3124-3130.
20. Bamber DE, Fryer AA, Strange RC, Elder JB, Deakin M, Rajagopal R, et al. Phenol sulphotransferase SULT1A1*1 genotype is associated with reduced risk of colorectal cancer. Pharmacogenetics 2001; 11: 679-685.
21. Loktionov A, Watson MA, Gunter M, Stebbings WSL, Speakman CTM, Bingham SA. Glutathione-S-transferase gene polymorphisms in colorectal cancer patients: interaction between GSTM1 and GSTM3 allele variants as a risk-modulating factor. Carcinogenesis 2001; 22: 1053-1060.
22. Nascimento H, Coy CSR, Teori MT, Boin I, Goes JRN, Costa FF, et al. Possible influence of glutathione S-transferase GSTT1 null genotype on age of onset of sporadic colorectal adenocarcinoma. Diseases Colon Rectum 2003; 46: 510-515.
23. Ye Z, Parry JM. Genetic polymorphisms in the cytochrome p4501A1, glutathione S-transferase M1 and T1, and susceptibility to colon cancer. Teratogenesis Carcinogenesis Mutagenesis 2002; 22: 385-392.
24. Browning M, Petronzelli F, Bicknell D, Krausa P, Rowan A, Tonks S, et al. Mechanisms of loss of HLA class I expression on colorectal tumor cells. Tissue Antigens 1996; 47: 364-371.
25. Kaklamanis L, Townsend A, Doussisanagnostopoulou IA, Mortensen N, Harris AL, Gatter KC. Loss of major histocompatibility complex-encoded transporter associated with antigen presentation (Tap) in colorectal cancer. Am J Pathol 1994; 145: 505-509.
26. Lal A, Lash AE, Altschul SF, Velculescu V, Zhang L, McLendon RE, et al. A public database for gene expression in human cancers. Cancer Res 1999; 59: 5403-5407.
27. Agrawal D, Chen TG, Irby R, Quackenbush J, Chambers AF, Szabo M, et al. Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst 2002; 94: 513-521.
28. Paoni NF, Feldman MW, Gutierrez LS, Ploplis VA, Castellino FJ. Transcriptional profiling of the transition from normal intestinal epithelia to adenomas and carcinomas in the APC(Min/+) mouse. Physiol Genomics 2003; 15: 228-235.
29. Wilson CL, Heppner KJ, Labosky PA, Hogan BLM, Matrisian LM. Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. Proc Natl Acad Sci U S A 1997; 94: 1402-1407.
30. Goss KJH, Brown PD, Matrisian LM. Differing effects of endogenous and synthetic inhibitors of metalloproteinases on intestinal tumorigenesis. Int J Cancer 1998; 78: 629-635.
31. Takeuchi N, Ichikawa Y, Ishikawa T, Momiyama N, Hasegawa S, Nagashima Y, et al. Matrilysin gene expression in sporadic and familial colorectal adenomas. Mol Carcinogenesis 1997; 19: 225-229.
32. Ishikawa T, Ichikawa Y, Mitsuhashi M, Momiyama N, Chishima T, Tanaka K, et al. Matrilysin is associated with progression of colorectal tumor. Cancer Lett 1996; 107: 5-10.
33. Newell KJ, Witty JP, Rodgers WH, Matrisian LM. Expression and localization of matrix-degrading metalloproteinases during colorectal tumorigenesis. Mol Carcinogenesis 1994; 10: 199-206.
34. Papadopoulou S, Scorilas A, Arnogianaki N, Papapanayiotou B, Tzimogiani A, Agnantis N, et al. Expression of gelatinase-A (MMP-2) in human colon cancer and normal colon mucosa. Tumor Biol 2001; 22: 383-389.
35. Brabletz T, Jung A, Dag S, Hlubek F, Kirchner T. Beta-catenin regulates the expression of the matrix metalloproteinase-7 in human colorectal cancer. Am J Pathol 1999; 155: 1033-1038.
36. Takahashi M, Tsunoda T, Seiki M, Nakamura Y, Furukawa Y. Identification of membrane-type matrix metalloproteinase-1 as a target of the beta-catenin/Tcf4 complex in human colorectal cancers. Oncogene 2002; 21: 5861-5867.
37. Li QL, Harju S, Peterson KR. Locus control regions - coming of age at a decade plus. Trends Genet 1999; 15: 403-408.
38. Coussens LM, Fingleton B, Matrisian LM. Cancer therapy - matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002; 295: 2387-2392.
39. Chen TA, Yang I, Irby R, Shain KH, Wang HG, Quackenbush J, et al. Regulation of caspase expression and apoptosis by adenomatous polyposis coli. Cancer Res 2003; 63: 4368-4374.
40. Lipton A, Ali SM, Leitzel K, Chinchilli V, Witters L, Engle L, et al. Serum osteoprotegerin levels in healthy controls and cancer patients. Clin Cancer Res 2002; 8: 2306-2310.